{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:13:33Z","timestamp":1762377213062},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11136-022-03193-0","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T14:02:45Z","timestamp":1658930565000},"page":"3331-3337","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective"],"prefix":"10.1007","volume":"31","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Fiteni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Peron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"issue":"26","key":"3193_CR1","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., et al. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495\u20132505.","journal-title":"New England Journal of Medicine"},{"key":"3193_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda, A., Floquet, A., Ledermann, J.A., Asher, R., Penson, R.T., Oza, A.M., et al. (2021). Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 22, 620\u2013631.","journal-title":"The lancet Oncology"},{"issue":"5","key":"3193_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","volume":"22","author":"M Friedlander","year":"2021","unstructured":"Friedlander, M., Moore, K. N., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., et al. (2021). Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): A randomised, phase 3 trial. The lancet Oncology, 22(5), 632\u2013642.","journal-title":"The lancet Oncology"},{"issue":"25","key":"3193_CR4","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I., Pautier, P., Pignata, S., P\u00e9rol, D., Gonz\u00e1lez-Mart\u00edn, A., Berger, R., et al. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine, 381(25), 2416\u20132428.","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"3193_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A., Pothuri, B., Vergote, I., DePont, C. R., Graybill, W., Mirza, M. R., et al. (2019). Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 381(25), 2391\u20132402.","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"3193_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., et al. (2016). Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine, 375(22), 2154\u20132164.","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 3","key":"3193_CR7","first-page":"A12","volume":"30","author":"G Freyer","year":"2020","unstructured":"Freyer, G., Pothuri, B., Han, S., Chase, D., Monk, B., Heitz, F., et al. (2020). 17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA\/ENGOT-OV26\/GOG-3012 trial. International Journal of Gynecological Cancer, 30(Suppl 3), A12.","journal-title":"International Journal of Gynecological Cancer"},{"key":"3193_CR8","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1016\/j.annonc.2020.08.949","volume":"31","author":"B Pothuri","year":"2020","unstructured":"Pothuri, B., Han, S., Chase, D., Heitz, F., Burger, R., Gaba, L., et al. (2020). 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Annals of Oncology, 31, S612\u2013S613.","journal-title":"Annals of Oncology"},{"issue":"8","key":"3193_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","volume":"19","author":"AM Oza","year":"2018","unstructured":"Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., del Campo, J. M., et al. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): Results from a double-blind, phase 3, randomised controlled trial. The lancet Oncology, 19(8), 1117\u20131125.","journal-title":"The lancet Oncology"},{"issue":"34","key":"3193_CR10","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1200\/JCO.19.00917","volume":"37","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A., Walder, L., N\u00f8ttrup, T. J., Bessette, P., Mahner, S., Gil-Martin, M., et al. (2019). Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: A TWiST analysis of the ENGOT-OV16\/NOVA trial. Journal of Clinical Oncology, 37(34), 3183\u20133191.","journal-title":"Journal of Clinical Oncology"},{"issue":"10106","key":"3193_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., et al. (2017). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet., 390(10106), 1949\u20131961.","journal-title":"The Lancet."},{"issue":"30","key":"3193_CR12","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1200\/JCO.19.03107","volume":"38","author":"AM Oza","year":"2020","unstructured":"Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., et al. (2020). Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma. Journal of Clinical Oncology, 38(30), 3494\u20133505.","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"3193_CR13","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., et al. (2019). Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. New England Journal of Medicine, 381(25), 2403\u20132415.","journal-title":"New England Journal of Medicine"},{"key":"3193_CR14","unstructured":"809MO Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint) - Annals of Oncology [Internet]. [cited 2022 Jan 4]. Available from: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(20)40944-5\/fulltext"},{"issue":"16","key":"3193_CR15","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.2014.56.7974","volume":"34","author":"F Bonnetain","year":"2016","unstructured":"Bonnetain, F., Fiteni, F., Efficace, F., & Anota, A. (2016). Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. Journal of Clinical Oncology, 34(16), 1953\u20131956.","journal-title":"Journal of Clinical Oncology"},{"key":"3193_CR16","unstructured":"Clinical-Trial-Endpoints-Approval-Cancer-Drugs-Biologics-final-guidance.pdf."},{"issue":"6","key":"3193_CR17","first-page":"e045105","volume":"11","author":"M Calvert","year":"2021","unstructured":"Calvert, M., King, M., Mercieca-Bebber, R., Aiyegbusi, O., Kyte, D., Slade, A., et al. (2021). SPIRIT-PRO Extension explanation and elaboration: Guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. British Medical Journal Open, 11(6), e045105.","journal-title":"British Medical Journal Open"},{"key":"3193_CR18","unstructured":"Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. The CONSORT PRO Extension. 2010; 9"},{"issue":"2","key":"3193_CR19","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","volume":"21","author":"C Coens","year":"2020","unstructured":"Coens, C., Pe, M., Dueck, A. C., Sloan, J., Basch, E., Calvert, M., et al. (2020). International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: Recommendations of the SISAQOL Consortium. The Lancet Oncology, 21(2), e83-96.","journal-title":"The Lancet Oncology"},{"issue":"12","key":"3193_CR20","doi-asserted-by":"publisher","first-page":"e892","DOI":"10.1016\/S2352-3026(20)30292-1","volume":"7","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty, R., Cannella, L., Cottone, F., & Efficace, F. (2020). Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: A systematic review. Lancet Haematology, 7(12), e892-901.","journal-title":"Lancet Haematology"},{"issue":"2","key":"3193_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ygyno.2020.09.007","volume":"159","author":"JZ Musoro","year":"2020","unstructured":"Musoro, J. Z., Coens, C., Greimel, E., King, M. T., Sprangers, M. A. G., Nordin, A., et al. (2020). Minimally important differences for interpreting European organisation for research and treatment of cancer (EORTC) quality of life questionnaire core 30 scores in patients with ovarian cancer. Gynecologic Oncology, 159(2), 515\u2013521.","journal-title":"Gynecologic Oncology"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-022-03193-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-022-03193-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-022-03193-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T08:29:52Z","timestamp":1666427392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-022-03193-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3193"],"URL":"https:\/\/doi.org\/10.1007\/s11136-022-03193-0","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"1 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fr\u00e9d\u00e9ric Fiteni has served on advisory boards for Astrazeneca, Clovis pharma and GSK. Julien Peron declares he has no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}